cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Delayed NYSE 03:22:45 12/09/26 am AEST			5-day change	1st Jan Change
0.4820 ^USD	+0.84%		+1.35%	-64.30%

03/09	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
17/08	Maxim Group Downgrades cbdMD to Hold From Buy	MT

Last Transcript : cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

14/08

More transcripts

Analysts' recommendations : cbdMD, Inc.

17/08	Maxim Group Downgrades cbdMD to Hold From Buy	MT
06/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors : cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
12/09/26	USD 0.4820	+0.84%	10,014
10/09/26	USD 0.4780	-2.83%	71,617
09/09/26	USD 0.4919	-1.56%	71,766
08/09/26	USD 0.4997	+5.07%	34,356
04/09/26	USD 0.4756	-1.12%	83,692

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4780

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	5.36M 4.61M 4.37M 3.96M 7.43M 512M 7.47M 51.9M 19.96M 260M 20.12M 19.67M 823M	P/E 2026 *	-1.45x	P/E 2027 *	-2.52x
Enterprise Value	5.36M 4.61M 4.37M 3.96M 7.43M 512M 7.47M 51.9M 19.96M 260M 20.12M 19.67M 823M	EV / Sales 2026 *	0.24x	EV / Sales 2027 *	0.19x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

03/09	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
17/08	Maxim Group Downgrades cbdMD to Hold From Buy	MT
14/08	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
14/08	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
15/07	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
14/07	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
08/07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
01/07	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
17/06	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
15/05	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
15/05	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
15/05	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
07/04	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI

02/09	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
14/08	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
11/08	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
04/08	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR
27/07	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ

1 day	+1.05%
1 week	+1.35%
Current month	-1.63%
1 month	-17.61%
3 months	-30.95%
6 months	-31.34%
Current year	-64.30%

1 week	0.47	0.5
1 month	0.45	0.62
Current year	0.45	1.34
1 year	0.45	2.56
3 years	0.45	13.84
5 years	0.45	820.8
10 years	0.45	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation : cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript : cbdMD, Inc.

Analysts' recommendations : cbdMD, Inc.

Press Releases : cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/4/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/4/26	William Raines	Free	Director	1,572	0.0150%
14/4/26	Bakari Sellers	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+0.84%	+1.35%	-31.04%	-95.70%	5.36M
ELI LILLY AND COMPANY	-0.07%	-2.37%	+48.37%	+88.41%	1,001B
JOHNSON & JOHNSON	-0.19%	-3.45%	+48.88%	+63.37%	642B
ABBVIE INC.	+1.13%	+0.45%	+16.98%	+72.85%	451B
ROCHE HOLDING AG	-0.38%	-3.59%	+28.24%	+35.57%	340B
NOVARTIS AG	-0.09%	-13.54%	+10.08%	+26.87%	263B
ASTRAZENECA PLC	-0.43%	-2.48%	-2.07%	+11.48%	247B
AMGEN INC.	-0.81%	-13.32%	+34.04%	+44.80%	207B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.08%	-59.58%	197B
GILEAD SCIENCES, INC.	-0.50%	-4.65%	+22.15%	+86.88%	180B
Average	-0.34%	-5.04%	+15.55%	+27.50%	352.63B
Weighted average by Cap.	-0.22%	-4.65%	+30.13%	+55.90%

	2026 *	2027 *
Net sales	21.92M 18.89M 17.89M 16.21M 30.41M 2.09B 30.57M 212M 81.69M 1.07B 82.33M 80.53M 3.37B	28.6M 24.64M 23.33M 21.14M 39.67M 2.73B 39.87M 277M 107M 1.39B 107M 105M 4.39B
Net income	-3.33M -2.87M -2.72M -2.46M -4.62M -318M -4.65M -32.29M -12.42M -162M -12.51M -12.24M -512M	-4.95M -4.26M -4.04M -3.66M -6.86M -473M -6.9M -47.92M -18.43M -240M -18.58M -18.17M -760M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time